Name | Type | Description | Interventions |
---|
1L-Control: mFOLFOX6 (Gastric Cancer) | Active Comparator | Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018. | - 5-Fluorouracil (5-FU)
- Leucovorin
- Oxaliplatin
|
1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer) | Experimental | Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018. | - 5-Fluorouracil (5-FU)
- Leucovorin
- Oxaliplatin
- Atezolizumab
- Cobimetinib
|
1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer) | Experimental | Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018. | - 5-Fluorouracil (5-FU)
- Leucovorin
- Oxaliplatin
- Atezolizumab
- Cobimetinib
|
1L-B: mFOLFOX6 + Atezo (Gastric Cancer) | Experimental | Participants in the 1L-B Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018. | - 5-Fluorouracil (5-FU)
- Leucovorin
- Oxaliplatin
- Atezolizumab
|
2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer) | Active Comparator | Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019. | |
2L-1: Atezo + Cobi (Gastric Cancer) | Experimental | Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019. | |
2L-2: Atezo + PEGPH20 (Gastric Cancer) | Experimental | Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019. | - PEGylated recombinant human hyaluronidase (PEGPH20)
- Atezolizumab
|
2L-3: Atezo + BL-8040 (Gastric Cancer) | Experimental | Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019. | |
2L-4: Atezo + Linagliptin (Gastric Cancer) | Experimental | Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019. | |
1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort) | Experimental | Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy. | - Atezolizumab
- Cisplatin
- Tiragolumab
- 5-Fluorouracil (5-FU)
|
1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort) | Experimental | Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy. | - Atezolizumab
- Cisplatin
- 5-Fluorouracil (5-FU)
|
1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort) | Active Comparator | Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy. | - Cisplatin
- 5-Fluorouracil (5-FU)
|
1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort) | Experimental | Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy. | |